Wen Qi Hu
Director/Board Member bei Beijing Mabworks Biotech Co., Ltd.
Profil
Wen Qi Hu is currently the Director, VP & Deputy General Manager at Beijing Mabworks Biotech Co., Ltd.
Prior to this, he held the position of Senior Director at Crownbio Bioscience Taicang Co. Ltd.
from 2013 to 2016.
He also served as an Associate Professor at Hunan Normal University from 1986 to 1996.
In addition, he was the Vice President at MabSpace Biosciences (Suzhou) Co., Ltd.
from 2016 to 2017.
Dr. Hu obtained his graduate degree from Nanjing Agricultural University in 1986, his undergraduate degree from Hunan Agricultural University in 1983, and his doctorate degree from Hunan Agricultural University in 1999.
Aktive Positionen von Wen Qi Hu
| Unternehmen | Position | Beginn |
|---|---|---|
Beijing Mabworks Biotech Co., Ltd.
 Beijing Mabworks Biotech Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Mabworks Biotech Co., Ltd. engages in the discovery, development, manufacturing and commercialization of therapeutic antibodies. It develops antibody drugs and macromolecular biological drugs. The firm’s products include MIL60, MIL62, MIL86, MBS301, MIL77, and MIL93. The company was founded on February 27, 2003 and is headquartered in Beijing, China. | Director/Board Member | 26.03.2020 |
Ehemalige bekannte Positionen von Wen Qi Hu
| Unternehmen | Position | Ende |
|---|---|---|
Suzhou Chuangsheng Pharmaceutical Group Co., Ltd.
 Suzhou Chuangsheng Pharmaceutical Group Co., Ltd. BiotechnologyHealth Technology MabSpace Biosciences (Suzhou) Co., Ltd. engages in the development of therapeutic antibodies for cancer and fibrotic diseases. Its products include humanized programmed death-ligand 1, humanized vascular endothelial growth factor receptors 2, humanized OX40, and humanized colony stimulating factor 1 receptor antibodies. It also offers programmed death-ligand 1 antibodies for Immunohistochemistry detection and soluble programmed death ligand 1 measurement. The company was founded by Xue Ming Qian on October 18, 2012 and is headquartered in Suzhou, China. | Corporate Officer/Principal | 01.05.2017 |
| Crownbio Bioscience Taicang Co. Ltd. | Director/Board Member | 01.08.2016 |
| Hunan Normal University | Corporate Officer/Principal | 01.02.1996 |
Ausbildung von Wen Qi Hu
| Nanjing Agricultural University | Graduate Degree |
| Hunan Agricultural University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Beijing Mabworks Biotech Co., Ltd.
Beijing Mabworks Biotech Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Mabworks Biotech Co., Ltd. engages in the discovery, development, manufacturing and commercialization of therapeutic antibodies. It develops antibody drugs and macromolecular biological drugs. The firm’s products include MIL60, MIL62, MIL86, MBS301, MIL77, and MIL93. The company was founded on February 27, 2003 and is headquartered in Beijing, China. | Health Technology |
Suzhou Chuangsheng Pharmaceutical Group Co., Ltd.
Suzhou Chuangsheng Pharmaceutical Group Co., Ltd. BiotechnologyHealth Technology MabSpace Biosciences (Suzhou) Co., Ltd. engages in the development of therapeutic antibodies for cancer and fibrotic diseases. Its products include humanized programmed death-ligand 1, humanized vascular endothelial growth factor receptors 2, humanized OX40, and humanized colony stimulating factor 1 receptor antibodies. It also offers programmed death-ligand 1 antibodies for Immunohistochemistry detection and soluble programmed death ligand 1 measurement. The company was founded by Xue Ming Qian on October 18, 2012 and is headquartered in Suzhou, China. | Health Technology |
| Crownbio Bioscience Taicang Co. Ltd. |
